Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


Articles published in Am J Clin Oncol

Retrieve available abstracts of 41 articles:
HTML format



Single Articles


    April 2024

  1. Pretreatment Characteristics of Carcinoid Tumors of the Lung Which Predict Aggressive Behavior: Erratum.
    Am J Clin Oncol. 2024;47:e1.
    PubMed    


  2. LIU X, Shen Q, Wen Y, Jiang Z, et al
    Diagnosis of Malignant Pulmonary Nodules Using a Combination of Tumor-associated Autoantibodies and Computed Tomography.
    Am J Clin Oncol. 2024;47:149-154.
    PubMed     Abstract available


    January 2024
  3. CHOU B, Lee JH, Saetern L, Venkatesulu BP, et al
    Bombarding Oligoprogression: Oncologic Outcomes After Radiation to Patients With Oligoprogressive Non-Small Cell Lung Cancer on Maintenance Systemic Therapy.
    Am J Clin Oncol. 2024 Jan 9. doi: 10.1097/COC.0000000000001077.
    PubMed     Abstract available


    December 2023
  4. BRASCHI EL, Morris CG, Yeung AR, De Leo AN, et al
    Impact of Maximum Point Dose Within the Planning Target Volume on Local Control of Nonsmall Cell Lung Cancer Treated With Stereotactic Body Radiotherapy.
    Am J Clin Oncol. 2023 Dec 25. doi: 10.1097/COC.0000000000001081.
    PubMed     Abstract available


    November 2023
  5. ALVAREZ CM, Aliru M, Gannavarapu BS, Song T, et al
    Impact of Pretreatment Weight Loss on Radiotherapy Utilization and Clinical Outcomes in Non-Small Cell Lung Cancer.
    Am J Clin Oncol. 2023 Nov 24. doi: 10.1097/COC.0000000000001053.
    PubMed     Abstract available


  6. YANG L, Lu X, Luo J, Huang D, et al
    Hyperfractionated Accelerated Radiotherapy Versus Stereotactic Body Radiotherapy in the Treatment of Limited-Stage Small Cell Lung Cancer: A Matched-Pair Analysis.
    Am J Clin Oncol. 2023 Nov 20. doi: 10.1097/COC.0000000000001066.
    PubMed     Abstract available


  7. CANTRELL JN, Acharya P, Vesely SK, Gunter TC, et al
    Pathologic Nodal Staging Before SBRT for Early-stage NSCLC Does Not Impact Overall Survival: A Propensity Score-matched NCDB Analysis.
    Am J Clin Oncol. 2023;46:503-511.
    PubMed     Abstract available


    October 2023
  8. ZHAO KX, Zhang YF, Zheng L, Pan YF, et al
    A Meta-analysis of Randomised Controlled Trials Comparing Combination Therapy as Second-line Treatment With Monotherapy in Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutation.
    Am J Clin Oncol. 2023 Oct 2. doi: 10.1097/COC.0000000000001047.
    PubMed     Abstract available


    September 2023
  9. YU S, Zhai S, Gong Q, Xiang C, et al
    Neoadjuvant Immunotherapy and Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Am J Clin Oncol. 2023 Sep 26. doi: 10.1097/COC.0000000000001046.
    PubMed     Abstract available


  10. ACIKGOZ Y, Yildirim FU, Esen SA, Ucar G, et al
    The Prognostic and Functional Impact of Sprouty 2 Expression in Non-small Cell Lung Cancer.
    Am J Clin Oncol. 2023 Sep 13. doi: 10.1097/COC.0000000000001044.
    PubMed     Abstract available


    August 2023
  11. ZHU Z, Zhang A
    Correlation of Lung Immune Prognostic Index With Efficacy of PD-1/PD-L1 Inhibitor Combined With Chemotherapy and Prognosis in Patients With Advanced Non-Small Cell Lung Cancer.
    Am J Clin Oncol. 2023 Aug 25. doi: 10.1097/COC.0000000000001035.
    PubMed     Abstract available


    July 2023
  12. GARCIA-FUMERO R, Fernandez-Lopez C, Calleja-Hernandez MA, Exposito-Ruiz M, et al
    Clinical Outcomes of First-line Therapies for Advanced Non-Small Cell Lung Cancer: A Systematic Review of Trials Published Between 2010 and 2020.
    Am J Clin Oncol. 2023 Jul 31. doi: 10.1097/COC.0000000000001031.
    PubMed     Abstract available


    June 2023
  13. LI F, Lv Q, Zhao S, Guo T, et al
    Prognostic Value of Pretreatment Serum Carcinoembryonic Antigen Level in 1130 Patients With Non-small Cell Lung Cancer: A Propensity Score Matching Cohort Study and Cumulative Mate-analysis.
    Am J Clin Oncol. 2023 Jun 27. doi: 10.1097/COC.0000000000001022.
    PubMed     Abstract available


    April 2023
  14. YANG H, Li D, Liu T
    Prognostic Relevance of Negative Lymph Node Count in Resected Stage I-IIIa Small-cell Lung Cancer.
    Am J Clin Oncol. 2023 Apr 27. doi: 10.1097/COC.0000000000001006.
    PubMed     Abstract available


  15. NIEDER C, Haukland EC, Mannsaker B, Dalhaug A, et al
    The LabPS score: Inexpensive, Fast, and Site-agnostic Survival Prediction.
    Am J Clin Oncol. 2023;46:178-182.
    PubMed     Abstract available


    March 2023
  16. AFSHARI S, Anker CJ, Kooperkamp HZ, Sprague BL, et al
    Trends and Outcomes of Salvage Lobectomy for Early-stage Non-Small Cell Lung Cancer.
    Am J Clin Oncol. 2023 Mar 24. doi: 10.1097/COC.0000000000001001.
    PubMed     Abstract available


  17. ASHA W, Koro S, Mayo Z, Yang K, et al
    Stereotactic Body Radiation Therapy for Sarcoma Pulmonary Metastases.
    Am J Clin Oncol. 2023 Mar 14. doi: 10.1097/COC.0000000000001000.
    PubMed     Abstract available


    February 2023
  18. HU YX, Guo LJ, Lin MQ, Lin QY, et al
    Efficacy and Prognostic Factors of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer.
    Am J Clin Oncol. 2023 Feb 20. doi: 10.1097/COC.0000000000000985.
    PubMed     Abstract available


  19. SAEED NA, Jin L, Amini A, Verma V, et al
    Utilization and Survival Impact of Hypofractionated Radiotherapy in Stage I Non-small Cell Lung Cancer.
    Am J Clin Oncol. 2023;46:66-72.
    PubMed     Abstract available


    January 2023
  20. DELUCE J, Maj D, Verma S, Breadner D, et al
    Efficacy and Toxicity of Combined Inhibition of EGFR and VEGF in Patients With Advanced Non-small Cell Lung Cancer Harboring Activating EGFR Mutations: A Systematic Review and Meta-analysis.
    Am J Clin Oncol. 2023 Jan 20. doi: 10.1097/COC.0000000000000976.
    PubMed     Abstract available


    December 2022
  21. YANG H, Liu T, Li M, Fang Z, et al
    Does Examined Lymph Node Count Influence Survival in Surgically Resected Early‑stage Pulmonary Typical Carcinoid Tumors?
    Am J Clin Oncol. 2022;45:506-513.
    PubMed     Abstract available


    November 2022
  22. HINOJOS M, Li X, Mikesell S, Studden S, et al
    Impact of Low-dose Chest CT Screening on the Association Between Rurality and Lung Cancer Outcomes.
    Am J Clin Oncol. 2022 Nov 3. pii: 00000421-990000000-00045.
    PubMed     Abstract available


    May 2022
  23. RUAN T, Jiang P, Li C, Pan G, et al
    A Proposal to Modify the 8th IASLC System: Is it Suitable for T4N2M0 Lung Adenocarcinoma to Be Placed in Stage IIIB?
    Am J Clin Oncol. 2022;45:215-222.
    PubMed     Abstract available


    April 2022
  24. JANG JK, Atay SM, Ding L, David EA, et al
    Patterns of Use of Stereotactic Body Radiation Therapy Compared With Surgery for Definitive Treatment of Primary Early-stage Non-small Cell Lung Cancer.
    Am J Clin Oncol. 2022;45:146-154.
    PubMed     Abstract available


    March 2022
  25. BRYANT AK, Yin H, Schipper MJ, Paximadis PA, et al
    Uptake of Adjuvant Durvalumab After Definitive Concurrent Chemoradiotherapy for Stage III Nonsmall-cell Lung Cancer.
    Am J Clin Oncol. 2022 Mar 11. pii: 00000421-900000000-98496.
    PubMed     Abstract available


  26. KUBICEK GJ, Khrizman P, Squillante C, Callahan K, et al
    Stereotactic Body Radiotherapy and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer: Single Arm Phase 2 Study.
    Am J Clin Oncol. 2022;45:129-133.
    PubMed     Abstract available


  27. MACBETH F, Treasure T
    The Biology and Systemic Treatments Influence Survival in Advanced Gastrointestinal Cancers While the Controlled Trial of Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) Found That Surgical Resection Could Only Have a Small If Any Effect.
    Am J Clin Oncol. 2022;45:135-136.
    PubMed    


    January 2022
  28. LIU J, Bratton E, Yu X, Ladbury C, et al
    Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC).
    Am J Clin Oncol. 2022 Jan 6. pii: 00000421-900000000-98513.
    PubMed     Abstract available


  29. BURNS S, Vella M, Paciorek A, Zhang L, et al
    Characteristics and Growth Rate of Lung Metastases in Patients With Primary Gastrointestinal Malignancies and Lung-dominant Metastatic Disease: A Retrospective Cohort Analysis.
    Am J Clin Oncol. 2022;45:22-27.
    PubMed     Abstract available


    November 2021
  30. DURU BIRGI S, Akgun Z, Hurmuz P, Akyurek S, et al
    Definitive Chemoradiotherapy Results in Synchronous Oligometastatic Non-small Cell Lung Cancer Patients: Turkish Society for Radiation Oncology Group Study (TROD 10-003).
    Am J Clin Oncol. 2021 Nov 30. pii: 00000421-900000000-98519.
    PubMed     Abstract available


  31. YOSHIMURA N, Sawa K, Nakai T, Matsumoto Y, et al
    Phase II Study of the Modified Weekly Nab-paclitaxel Regimen in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer.
    Am J Clin Oncol. 2021 Nov 10. pii: 00000421-900000000-98525.
    PubMed     Abstract available


    October 2021
  32. RITTBERG R, Banerji S, Kim JO, Rathod S, et al
    Treatment and Prevention of Brain Metastases in Small Cell Lung Cancer.
    Am J Clin Oncol. 2021 Oct 11. pii: 00000421-900000000-98528.
    PubMed     Abstract available


    September 2021
  33. WILLIAMS NR, Treasure T, Macbeth F, Fallowfield L, et al
    The Prospective Observational Cohort and the Nested Randomized Controlled Trial in the Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC Study) Question the Reliance on Existing Evidence for the Magnitude of Benefit From Lung Metastasectomy.
    Am J Clin Oncol. 2021;44:502-503.
    PubMed    


  34. AMIN M, Gao F, Terrero G, Picus J, et al
    Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
    Am J Clin Oncol. 2021;44:443-448.
    PubMed     Abstract available


    August 2021
  35. BATRA A, Yusuf D, Hurry M, Walton RN, et al
    A Population-based Study of Treatment Patterns and Survival of Patients With De Novo Stage IV Non-Small Cell Lung Cancer.
    Am J Clin Oncol. 2021 Aug 11. pii: 00000421-900000000-98537.
    PubMed     Abstract available


  36. YURKIEWICZ IR, Zhou M, Ganjoo KN, Charville GW, et al
    Management Strategies for Patients With Epithelioid Hemangioendothelioma: Charting an Indolent Disease Course.
    Am J Clin Oncol. 2021;44:419-422.
    PubMed     Abstract available


    June 2021
  37. MORTMAN KD, Devlin J, Giang B, Mortman R, et al
    Patient Adherence in an Academic Medical Center's Low-dose Computed Tomography Screening Program.
    Am J Clin Oncol. 2021;44:264-268.
    PubMed     Abstract available


    May 2021
  38. TUMINELLO S, Petralia F, Veluswamy R, Wang P, et al
    Prognostic Value of the Tumor Immune Microenvironment for Early-stage, Non-Small Cell Lung Cancer.
    Am J Clin Oncol. 2021 May 19. pii: 00000421-900000000-98563.
    PubMed     Abstract available


  39. ROH J, Eom JS, Lee MK, Kim J, et al
    Prognostic Factors of Second-line Immune Checkpoint Inhibitors in Patients With Advanced-stage Non-Small Cell Lung Cancer: A Multicenter, Retrospective Study.
    Am J Clin Oncol. 2021 May 17. pii: 00000421-900000000-98562.
    PubMed     Abstract available


  40. YANG W, Zhang Y, Xia D, Xu X, et al
    The Immunosuppression of Etoposide Deserves Attention in Chemoimmunotherapy.
    Am J Clin Oncol. 2021;44:224-225.
    PubMed    


    March 2021
  41. PARSAI S, Sedor G, Smile TD, Scott J, et al
    Multiple Site SBRT in Pediatric, Adolescent, and Young Adult Patients With Recurrent and/or Metastatic Sarcoma.
    Am J Clin Oncol. 2021;44:126-130.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.